Related Experiment Videos
Structure-activity relationships among desazadesferrithiocin analogues
Raymond J Bergeron1, Jan Wiegand, James S McManis
1Department of Medicinal Chemistry, University of Florida, Gainesville, Florida 32610, USA.
Advances in Experimental Medicine and Biology
|February 8, 2003
Summary
Researchers modified desferrithiocin, an iron chelator, to create safer, orally active drugs. Key structural features were identified, and introducing a hydroxy group significantly reduced toxicity while maintaining iron-clearing ability.
Area of Science:
- Medicinal Chemistry
- Pharmacology
- Natural Product Synthesis
Background:
- Desferrithiocin, a natural siderophore, serves as a basis for developing orally active iron chelators.
- Existing iron chelators often have limitations in oral activity and therapeutic window.
Purpose of the Study:
- To systematically investigate the structure-activity relationship of desferrithiocin for oral iron chelation.
- To identify key structural requirements for efficacy and explore modifications to reduce toxicity.
Main Methods:
- Structure-activity relationship (SAR) studies on desferrithiocin analogues.
- Synthesis and evaluation of desazadesferrithiocin analogues with modified aromatic rings.
- Toxicity assessments of modified iron chelators.
Main Results:
- Specific distances between ligating centers and an intact thiazoline ring are critical for desferrithiocin activity.
- Benz-fusions did not enhance tissue residence time or iron-clearing efficiency.
- Introduction of a 4'-hydroxy group in desazadesferrithiocin analogues significantly reduced toxicity with minimal impact on iron-clearing efficacy.
Conclusions:
- Optimal design of desferrithiocin-based iron chelators requires maintaining specific structural features, including the (S)-configuration at C-4.
- Modifying the redox potential of the aromatic ring, specifically through hydroxylation, can ameliorate toxicity.
- It is feasible to develop siderophore-based iron chelators with improved safety profiles while retaining therapeutic efficacy.